480 related articles for article (PubMed ID: 19808125)
21. Starting insulin therapy with basal insulin analog or premix insulin analog in T2DM: a pooled analysis of treat-to-target trials.
Fonseca V; Davidson J; Home P; Snyder J; Jellinger P; Dyhr Toft A; Barnett A
Curr Med Res Opin; 2010 Jul; 26(7):1621-8. PubMed ID: 20429817
[TBL] [Abstract][Full Text] [Related]
22. A comparison of biphasic insulin aspart and insulin glargine administered with oral antidiabetic drugs in type 2 diabetes mellitus--a systematic review and meta-analysis.
Rys P; Wojciechowski P; Siejka S; Małecki P; Hak L; Malecki MT
Int J Clin Pract; 2014 Mar; 68(3):304-13. PubMed ID: 24471814
[TBL] [Abstract][Full Text] [Related]
23. A comparison of twice-daily biphasic insulin aspart 70/30 and once-daily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy: a randomized, open-label study.
Ligthelm RJ; Gylvin T; DeLuzio T; Raskin P
Endocr Pract; 2011; 17(1):41-50. PubMed ID: 20713345
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open-label, 2:1 randomized, treat-to-target trial.
Yang W; Ma J; Hong T; Liu M; Miao H; Peng Y; Wang C; Xu X; Yang T; Nielsen AM; Pan L; Liu W; Zhao W
Diabetes Obes Metab; 2019 Jul; 21(7):1652-1660. PubMed ID: 30869183
[TBL] [Abstract][Full Text] [Related]
25. Predictors of achieving HbA(1c) <7% and no hypoglycaemia 6 months after initiation of biphasic insulin aspart 30 in patients with type 2 diabetes in the IMPROVE study.
Valensi P; Shaban J; Benroubi M; Kawamori R; Borzì V; Shah S; Wenying Y; Prusty V; Hansen JB; Gumprecht J;
Curr Med Res Opin; 2013 Jun; 29(6):601-9. PubMed ID: 23488447
[TBL] [Abstract][Full Text] [Related]
26. Postprandial glycemic control with biphasic insulin aspart in patients with type 1 diabetes.
Hermansen K; Vaaler S; Madsbad S; Dalgaard M; Zander M; Begtrup K; Soendergaard K
Metabolism; 2002 Jul; 51(7):896-900. PubMed ID: 12077738
[TBL] [Abstract][Full Text] [Related]
27. An exploratory study of the effect of using high-mix biphasic insulin aspart in people with type 2 diabetes.
Dashora U; Ashwell SG; Home PD
Diabetes Obes Metab; 2009 Jul; 11(7):680-7. PubMed ID: 19527481
[TBL] [Abstract][Full Text] [Related]
28. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial.
Liebl A; Prager R; Binz K; Kaiser M; Bergenstal R; Gallwitz B;
Diabetes Obes Metab; 2009 Jan; 11(1):45-52. PubMed ID: 18643839
[TBL] [Abstract][Full Text] [Related]
29. Biphasic insulin aspart in type 2 diabetes mellitus: an evidence-based medicine review.
Gough SC; Tibaldi J
Clin Drug Investig; 2007; 27(5):299-324. PubMed ID: 17451279
[TBL] [Abstract][Full Text] [Related]
30. Clinical safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes patients switched from biphasic human insulin 30: results from the Indonesian cohort of the A₁chieve study.
Soewondo P; Lindarto D; Wibisono S; Renaldi O; Dalem-Pemayun TG
Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S41-6. PubMed ID: 23647718
[TBL] [Abstract][Full Text] [Related]
31. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 twice daily in insulin-experienced Japanese subjects with uncontrolled type 2 diabetes: Subgroup analysis of a Pan-Asian, treat-to-target Phase 3 Trial.
Taneda S; Hyllested-Winge J; Gall MA; Kaneko S; Hirao K
J Diabetes; 2017 Mar; 9(3):243-247. PubMed ID: 27059529
[TBL] [Abstract][Full Text] [Related]
32. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes.
Hermansen K; Colombo M; Storgaard H; ØStergaard A; Kølendorf K; Madsbad S
Diabetes Care; 2002 May; 25(5):883-8. PubMed ID: 11978685
[TBL] [Abstract][Full Text] [Related]
33. Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus.
Niskanen L; Jensen LE; Råstam J; Nygaard-Pedersen L; Erichsen K; Vora JP
Clin Ther; 2004 Apr; 26(4):531-40. PubMed ID: 15189750
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and tolerability of self-titrated biphasic insulin aspart 70/30 in patients aged >65 years with type 2 diabetes: an exploratory post hoc subanalysis of the INITIATEplus trial.
Oyer DS; Shepherd MD; Coulter FC; Bhargava A; Deluzio AJ; Chu PL; Trippe BS;
Clin Ther; 2011 Jul; 33(7):874-83. PubMed ID: 21741089
[TBL] [Abstract][Full Text] [Related]
35. Does serum 1,5-anhydroglucitol establish a relationship between improvements in HbA1c and postprandial glucose excursions? Supportive evidence utilizing the differential effects between biphasic insulin aspart 30 and insulin glargine.
Moses AC; Raskin P; Khutoryansky N
Diabet Med; 2008 Feb; 25(2):200-5. PubMed ID: 18290862
[TBL] [Abstract][Full Text] [Related]
36. Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT.
Strojek K; Bebakar WM; Khutsoane DT; Pesic M; Smahelová A; Thomsen HF; Kalra S
Curr Med Res Opin; 2009 Dec; 25(12):2887-94. PubMed ID: 19821654
[TBL] [Abstract][Full Text] [Related]
37. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
[TBL] [Abstract][Full Text] [Related]
38. Baseline characteristics of the Indian cohort from the IMPROVE study: a multinational, observational study of biphasic insulin aspart 30 treatment for type 2 diabetes.
Shah S; Das AK; Kumar A; Unnikrishnan AG; Kalra S; Baruah MP; Ganapathi B; Sahay RK
Adv Ther; 2009 Mar; 26(3):325-35. PubMed ID: 19252828
[TBL] [Abstract][Full Text] [Related]
39. [Improvement in glycemic control, cardiovascular risk factors and anthropometric data in type 2 diabetic patients after the switch from biphasic human insulin to biphasic premix analog insulin aspart].
Gero L; Gyimesi A; Hidvégi T; Jánosi I
Orv Hetil; 2009 Aug; 150(35):1637-47. PubMed ID: 19692308
[TBL] [Abstract][Full Text] [Related]
40. Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial.
Fulcher GR; Christiansen JS; Bantwal G; Polaszewska-Muszynska M; Mersebach H; Andersen TH; Niskanen LK;
Diabetes Care; 2014 Aug; 37(8):2084-90. PubMed ID: 24812432
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
